THER-06. THERAPEUTIC EFFICACY OF RRV-MEDIATED PRODRUG ACTIVATOR GENE THERAPY IN CLINICAL TRIALS OF RECURRENT HIGH-GRADE GLIOMA AND IN MURINE ORTHOTOPIC MODELS OF INTRACEREBRAL GLIOMA AND INTRACEREBELLAR MEDULLOBLASTOMA

Toca 511, a clinical-stage tumor-selective retroviral replicating vector (RRV), encodes optimized yeast cytosine deaminase (CD), which converts the prodrug 5-fluorocytosine (5-FC) to the active drug 5-fluorouracil (5-FU) within infected cancer cells. In preclinical models of intracerebral glioblasto...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Angela, Collins, Sara, Inagaki, Akihito, Armstrong, Valerie, Robbins, David, Ayad, Nagi, Gruber, Harry, Jolly, Douglas, Cloughesy, Timothy, Kasahara, Noriyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Viral/Gene Therapy and other Novel Therapies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715530/
http://dx.doi.org/10.1093/neuonc/noaa222.856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715530/
http://dx.doi.org/10.1093/neuonc/noaa222.856

Ejemplares similares